Promoted Content
Promoted Content

Find Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) in Phase I Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BX003

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BX003

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            Results support the potential of a phage therapy approach for the treatment of both IBD and PSC, demonstrating the ability to identify and select phage with direct relevance to patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DUR-928

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            The additional biomarker data suggests that epigenetic modulation by DUR-928 is worthy of further study in NASH patients. DURECT's lead drug candidate, DUR-928, is an endogenous sulfated oxysterol and an epigenetic regulator.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MET409

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET409

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 01, 2020

            Details:

            The findings showed robust and sustained FXR activation, which Metacrine believes is key to optimizing therapeutic benefits. Combined with a favorable pharmacological and tolerability profile, the results support the therapeutic potential of MET409 for patients with NASH.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB1211

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GB1211

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 15, 2020

            Details:

            GB1211 has been shown to be effective in several pre-clinical fibrosis models, without any signs of toxicity. Galectin-3 plays a key role in fibrosis development through cellular activation and production of collagen.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EP547

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: EP547

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Sanofi Ventures

            Deal Size: $77.5 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing September 14, 2020

            Details:

            Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TERN-201

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-201

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 10, 2020

            Details:

            Terns recently completed a Phase 1 clinical study of TERN-201, which demonstrated that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings observed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MET409

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET409

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            MET409 demonstrated notable improvements in decreased liver fat content and differentiated impacts on pruritus and LDL cholesterol after 12 weeks of treatment in NASH patients .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AXA1125,AXA1957

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1125

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            Poster presentation contains data demonstrating AXA1125’s multifactorial effects on markers of metabolism, inflammation and fibrosis in subjects with NAFLD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CB4211

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CB4211

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Roth Capital Partners

            Deal Size: $15.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering August 25, 2020

            Details:

            CohBar intends to use the net proceeds from the offering, together with its existing cash resources, for general corporate purposes, funding preclinical and clinical development of its peptides, increasing working capital, operating expenses and capital expenditures.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MET409

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MET409

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            Details:

            U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET409, the company’s lead farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).